Dr. Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto to complete a PhD under the supervision of Dr. Jeremy Squire in prostatic carcinogenesis. He has since joined the Department of Medical Oncology at The Princess Margaret, specialising in genito-urinary malignancy and melanoma. He is currently an Assistant Professor with the University of Toronto and a clinician-scientist at the Univeisty Health Network. His current interests include the unfolded protein response (working with Dr. Brad Wouters), autophagy in prostatic carcinogenesis, translational research in GU and melanoma trials and clinical trial design. He also has an interest in epistemiology in medicine.
Dr. Jennifer Knox is an Associate Professor of Medicine at the University of Toronto and a staff member of the Department of Medical Oncology of The Princess Margaret. She completed a Masters of Science in molecular biology and her medical degree at the University of Toronto. After completing her medical oncology specialty training she completed a fellowship at The Princess Margaret focused on new drug development and clinical trials. Her research interests include clinical and translational research in new drug development, GI and GU malignancies.
Dr. Sridhar is a Medical Oncologist at The Princess Margaret and an Assistant Professor of Medicine at the University of Toronto. Dr. Sridhar completed her medical school and training at the University of Ottawa and University of Toronto. Her academic and research interests include bladder cancer, novel therapeutics and clinical trials.
Dr.Tannock obtained his PhD in London, England for studies of cell population kinetics. After postdoctoral studies at MD Anderson Hospital, he studied medicine at University of Pennsylvania. He completed training as a Medical Oncologist at The Princess Margaret in 1978, and apart from a sabbatical year in France has remained here as a clinician/scientist. Dr. Tannock’s clinical research has investigated methodological issues related to cancer clinical trials, with emphasis on endpoints of clinical benefit. He chaired randomized clinical trials for men with metastatic prostate cancer that led to licensing of current chemotherapy. His laboratory-based research evaluates effects of the solid tumour microenvironment on outcome of cancer therapy.